Oncology and Solid Tumors
Nykode Therapeutics ASA focuses on solid tumor oncology across locally advanced and metastatic disease settings, with interest in cancers that remain difficult to treat in later stages of progression.
- Non-small cell lung carcinoma
- Renal cell carcinoma
- Urothelial carcinoma
- Gastric and gastroesophageal junction cancer
The clinical portfolio also includes triple-negative breast cancer, cervical cancer, anal cancer, and head and neck squamous cell carcinoma.
Head and Neck Cancer and HPV16-Associated Disease
A major area of interest is unresectable recurrent or metastatic HPV16-positive oropharyngeal head and neck squamous cell carcinoma, reflecting a strong focus on virus-associated malignancies within the broader head and neck oncology field.
- Oropharyngeal squamous cell carcinoma
- HPV16-positive tumors
- Recurrent and metastatic head and neck cancer
This area links viral oncology with advanced head and neck cancer management.
Cancer Immunotherapy
The sponsor’s studies center on immuno-oncology, with combinations designed to support antigen-specific immune responses in patients with advanced malignancies.
- PD-1 inhibitor combinations
- Checkpoint-based immunotherapy
- Immune response activation
Current research includes pairing investigational cancer immunotherapies with established immunotherapy agents such as pembrolizumab and atezolizumab.
Therapeutic Innovation in Advanced Malignancy
Clinical activity is concentrated in treatment-resistant and advanced-stage cancers, with attention to patients who have limited options across multiple tumor types and disease settings.
- Advanced-stage oncology
- Combination cancer therapy
- Multitumor treatment development
The company’s research footprint spans Europe and multiple active countries, with collaboration across clinical research sites supporting its oncology programs.
